Rifaximin is a minimally-absorbed, gut-selective antibiotic. Its healthspan relevance lies in its ability to reduce small intestinal bacterial overgrowth (SIBO) and modulate the gut microbiome, thereby decreasing gut-derived inflammation and endotoxin load (LPS) that can contribute to systemic aging processes. By improving gut barrier integrity without significant systemic side effects, it addresses a key source of chronic, low-grade inflammation.
Verdict
A powerful tool for specific gut issues, not a general longevity drug.
HEALTHSPAN IMPACT
Moderate
RISK LEVEL
Low
EVIDENCE GRADE
B
MONTHLY COST
$2000 - $3000
Protocol
- A typical course is 550mg taken three times daily for 14 days to reduce gut dysbiosis.
Flags
- Prescription-only and requires medical diagnosis (e.g., SIBO) and supervision.
- Extremely high cost if not covered by insurance for its specific indication.
- Risk of C. difficile-associated diarrhea, although lower than with systemic antibiotics.
- Potential for altering the gut microbiome, with unknown long-term consequences from repeated use.